Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2023-06-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms
NCT04012294
Effect of Allopurinol Treatment on Insulin Resistance
NCT02008968
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
NCT00987415
The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
NCT00978653
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
NCT00793585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
placebo
Placebo
placebo tablet
allopurinol
Allopurinol Tablet
allopurinol 300
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol Tablet
allopurinol 300
Placebo
placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khadija Ahmed Mhrose Glal
dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALLOU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.